GlassScriptPhysician profile
Jesus Zepeda
NPI 1891932083
$9,734.25
in general payments reported to CMS, 2019-2025
34 companies · $3,193 in 2025
The $3,193 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,102 · 2022: $1,154 · 2023: $1,509 · 2024: $2,776 · 2025: $3,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,410 · Education: $50.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,409.82 |
| Education | $50.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,945.13 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $1,272.32 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $677.07 | 2024-2025 | Tepezza, Repatha, Repatha |
| Dexcom, INC. | $581.47 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $539.73 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $472.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $422.82 | 2022-2025 | |
| Ascensia Diabetes Care US INC. | $412.53 | 2024-2025 | |
| Averitas Pharma INC. | $293.08 | 2024-2025 | Qutenza |
| Beta Bionics, INC. | $277.63 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Insulet Corporation | $275.29 | 2021-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $258.32 | 2022-2025 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $237.51 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $227.12 | 2025 | Yorvipath |
| Antares Pharma, INC. | $177.65 | 2022-2024 | Xyosted |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.36 | 2025 | Jardiance |
| Horizon Therapeutics Plc | $140.44 | 2022-2023 | Tepezza |
| Medtronic, INC. | $135.06 | 2024-2025 | Minimed 780g, Mycarelink |
| Alexion Pharmaceuticals, INC. | $131.64 | 2024 | |
| Tandem Diabetes Care, INC. | $130.73 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Currax Pharmaceuticals LLC | $123.12 | 2023-2025 | Contrave, Nexletol |
| Ibsa Pharma INC. | $111.26 | 2024-2025 | Tirosint, Licart, Flector |
| Corcept Therapeutics | $102.33 | 2024-2025 | Korlym |
| Aurinia Pharma U.S., INC. | $99.90 | 2024 | Lupkynis |
| Becton, Dickinson and Company | $76.74 | 2022 | |
| Embecta Corp. | $74.19 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Mannkind Corporation | $71.37 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $68.76 | 2025 | |
| Sanofi-Aventis U.S. LLC | $64.44 | 2024 | |
| Sequel Med Tech, LLC | $61.17 | 2025 | Twiist |
| Abbvie INC. | $55.11 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.31 | 2025 | |
| Bigfoot Biomedical INC | $24.84 | 2022 | |
| Kyowa Kirin, INC. | $21.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Zepeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.